Vanguard Group Inc. Purchases 1,373,209 Shares of Bristol-Myers Squibb (NYSE:BMY)

Vanguard Group Inc. increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 0.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 189,944,516 shares of the biopharmaceutical company's stock after acquiring an additional 1,373,209 shares during the period. Vanguard Group Inc. owned approximately 9.37% of Bristol-Myers Squibb worth $10,743,262,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of BMY. Swedbank AB raised its stake in Bristol-Myers Squibb by 0.9% during the third quarter. Swedbank AB now owns 3,139,552 shares of the biopharmaceutical company's stock valued at $162,440,000 after buying an additional 28,427 shares during the last quarter. United Bank raised its position in shares of Bristol-Myers Squibb by 2.7% in the 3rd quarter. United Bank now owns 17,322 shares of the biopharmaceutical company's stock worth $896,000 after purchasing an additional 456 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in Bristol-Myers Squibb by 4.9% in the 3rd quarter. Thrivent Financial for Lutherans now owns 116,801 shares of the biopharmaceutical company's stock worth $6,044,000 after purchasing an additional 5,407 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Bristol-Myers Squibb in the 3rd quarter worth about $3,579,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in Bristol-Myers Squibb during the 3rd quarter valued at about $319,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Remove Ads

Bristol-Myers Squibb Price Performance

Shares of BMY traded down $0.31 during mid-day trading on Thursday, reaching $58.90. The stock had a trading volume of 8,751,197 shares, compared to its average volume of 12,156,392. The firm has a market cap of $119.52 billion, a price-to-earnings ratio of -13.33, a PEG ratio of 2.07 and a beta of 0.43. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The business has a fifty day moving average of $58.47 and a 200 day moving average of $56.17. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Equities analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 4.21%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently -56.11%.

Analyst Ratings Changes

BMY has been the topic of several analyst reports. Citigroup upped their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Bank of America reaffirmed a "neutral" rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Cantor Fitzgerald lifted their target price on Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Wells Fargo & Company upped their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a report on Friday, February 7th. Finally, Jefferies Financial Group upgraded Bristol-Myers Squibb from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $63.00 to $70.00 in a report on Monday, December 16th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of "Hold" and a consensus price target of $57.86.

Insider Buying and Selling

In related news, EVP Samit Hirawat bought 1,823 shares of the stock in a transaction dated Friday, February 14th. The shares were purchased at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the acquisition, the executive vice president now owns 63,932 shares of the company's stock, valued at $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.